Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
128 studies found for:    Open Studies | "Lupus Erythematosus, Systemic"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Lupus Erythematosus, Systemic"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Effect of Qi Gong Training on Quality of Life in Patients With Systemic Lupus Erythematous (LuQi)
Condition: Lupus Erythematosus, Systemic
Intervention: Other: Qi Gong
2 Recruiting TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: TAB08;   Other: Placebo
3 Not yet recruiting A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: JNJ-56022473;   Drug: Placebo
4 Recruiting A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Biological: ALX-0061;   Biological: Placebo
5 Recruiting A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Active Systemic Lupus Erythematosus (SLE)
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Repository corticotropin injection;   Drug: Placebo gel
6 Recruiting A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: IPP-201101;   Drug: Placebo;   Other: Standard of Care
7 Recruiting Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients
Condition: Systemic Lupus Erythematosus
Interventions: Drug: MT-1303 Low dose;   Drug: MT-1303 High dose
8 Recruiting Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo
9 Recruiting A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
Condition: Systemic Lupus Erythematosus
Interventions: Drug: CC-220;   Drug: Placebo
10 Recruiting Walk With Ease Program For Patients With Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Other: "Walk With Ease"
11 Recruiting A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Ustekinumab IV;   Drug: Placebo Infusion;   Drug: Placebo SC;   Drug: Ustekinumab SC;   Other: Concomitant Medication
12 Recruiting Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo
13 Recruiting Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo
14 Not yet recruiting Using the Cholinergic Anit-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain
Conditions: Lupus Erythematosus, Systemic;   Musculoskeletal Pain
Interventions: Device: Vagus nerve stimulation;   Device: Sham vagus nerve stimulation
15 Recruiting Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: prednisone discontinuation
16 Recruiting Study of Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention:
17 Recruiting A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus (SLE)
Interventions: Drug: Placebo;   Drug: Dapirolizumab pegol (DZP)
18 Recruiting Systemic Lupus Erythematosus in Gullah Health
Condition: Systemic Lupus Erythematosus
Intervention:
19 Recruiting Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
Condition: Systemic Lupus Erythematosus
Interventions: Biological: BENLYSTA;   Other: SLE treatment
20 Recruiting Nelfinavir in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Nelfinavir

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.